drugset / Trial / NCT07150377
A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma
Phase 2
Not yet recruiting
41 enrolled
The Second Affiliated Hospital of Shandong First Medical University
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy of Iparomlimab and Tuvonralimab in combination with Lenvatinib and TACE for advanced hepatocellular carcinoma by assessing Progression-Free Survival (PFS).
Timeline
- Start
- 2025-08-24
- Primary completion
- 2026-08-24
- Completion
- 2028-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Tuvonralimab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Background | Lenvatinib | Small molecule | 8 mg | Oral |
| Background | Lenvatinib | Small molecule | 12 mg | Oral |